Administration of Autologous T-Cells Genetically Engineered to Express T-Cell Receptors Reactive Against Neoantigens in People With Metastatic Cancer | ClinicalTrials HQ

Ask about research services

Swipe the table sideways for more columns.

Trial	Conditions	Status	Phase	Updated	More info	NCT ID
Administration of Autologous T-Cells Genetically Engineered to Express T-Cell Receptors Reactive Against Neoantigens in People With Metastatic Cancer	Adnexal Diseases, Blood Protein Disorders, Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications, Genital Diseases, Hemic and Lymphatic Diseases, Male Urogenital Diseases, Neoplasms by Histologic Type, Neoplasms by Site, Neoplasms, Germ Cell and Embryonal, Neoplasms, Nerve Tissue, Skin and Connective Tissue Diseases, Thoracic Neoplasms, Urogenital Diseases, Urogenital Neoplasms, breast cancer, breast disorder, breast neoplasm, bronchial neoplasm, bronchogenic carcinoma, cardiovascular disorder, endocrine system disorder, female reproductive system disorder, female reproductive system neoplasm, gonadal disorder, hematologic disorder, hemorrhagic disease, immune system disorder, immunoproliferative disorder, lung disorder, lung neoplasm, lymphoproliferative syndrome, malignant endocrine neoplasm, monoclonal gammopathy, neoplasm, neuroendocrine neoplasm, non-small cell lung carcinoma, ovarian cancer, ovarian disorder, plasma cell neoplasm, primitive neuroectodermal tumor, respiratory system disorder, respiratory tract neoplasm, skin disorder, vascular disorder, vascular hemostatic disease	Recruiting	Phase 2	2026-09-28		NCT03412877

1 results · Page 1 of 1

Swipe the table sideways for more columns.

Organizations	Linked trials
National Cancer Institute (NCI)	3015

1 results · Page 1 of 1

Swipe the table sideways for more columns.

Research sites	City	Country	Linked trials
National Institutes of Health Clinical Center	Bethesda	United States	800